Patents Assigned to Incyte Pharmaceuticals
-
Publication number: 20020102652Abstract: The present invention provides a novel human integral membrane (MLF3) and polynucleotides which identify and encode MLF3. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding MLF3 and a method for producing MLF3. The invention also provides for agonists, antibodies, or antagonists specifically binding MLF3, and their use, in the prevention and treatment of diseases associated with expression of MLF3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding MLF3 for the treatment of diseases associated with the expression of MLF3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding MLF3.Type: ApplicationFiled: December 17, 2001Publication date: August 1, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Publication number: 20020102585Abstract: The invention provides two human prostate growth-associated membrane proteins (PGAMP) and polynucleotides which identify and encode PGAMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of PGAMP.Type: ApplicationFiled: September 26, 2001Publication date: August 1, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Publication number: 20020102710Abstract: The present invention provides a human apoptosis regulator protein (APRG) and polynucleotides which identify and encode APRG. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding APRG and a method for producing APRG. The invention also provides for agonists, antibodies, or antagonists specifically binding APRG, and their use, in the prevention and treatment of diseases associated with expression of APRG. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding APRG for the treatment of diseases associated with the expression of APRG. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding APRG.Type: ApplicationFiled: September 19, 2001Publication date: August 1, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Jennifer L. Hillman
-
Publication number: 20020102654Abstract: The invention provides human thioredoxin proteins (TRXP) and polynucleotides which identify and encode TRXP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of TRXP.Type: ApplicationFiled: September 17, 2001Publication date: August 1, 2002Applicant: Incyte Pharmaceuticals, IncInventors: Y. Tom Tang, Neil C. Corley, Karl J. Guegler, Chandra Patterson, Mariah R. Baughn
-
Publication number: 20020103342Abstract: The invention provides a human cornichon protein (CORN) and polynucleotides which identify and encode CORN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of CORN.Type: ApplicationFiled: January 10, 2002Publication date: August 1, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Publication number: 20020098474Abstract: The invention provides a human short-chain dehydrogenase (HSCD) and polynucleotides which identify and encode HSCD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HSCD.Type: ApplicationFiled: December 4, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Neil C. Corley
-
Publication number: 20020098561Abstract: The invention provides a novel human ATPase inhibitor protein (HATPI) and polynucleotides which identify and encode HATPI. The invention also provides genetically engineered expression vectors and host cells containing the nucleic acid sequences encoding HATPI. The invention also provides pharmaceutical compositions containing HATPI or antagonists to HATPI, and in the use of these compositions for the treatment of diseases associated with the expression of HATPI. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HATPI for the treatment of diseases associated with the expression of HATPI. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HATPI or anti-HATPI antibodies which specifically bind to HATPI.Type: ApplicationFiled: October 9, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventor: Jennifer L. Hillman
-
Publication number: 20020098569Abstract: The invention provides three human proteins associated with cell proliferation, referred to collectively as “APOP” and individually as “APOP-1”, “APOP-2”, and “APOP-3”, and polynucleotides which identify and encode APOP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of APOP.Type: ApplicationFiled: June 28, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Henry Yue, Preeti Lal, Purvi Shah, Neil C. Corley
-
Publication number: 20020099011Abstract: The invention provides human membrane recycling proteins (HMRP) and polynucleotides which identify and encode HMRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HMRP.Type: ApplicationFiled: April 24, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Purvi Shah, Neil C. Corley
-
Publication number: 20020098566Abstract: The invention provides a human nucleolin-like protein (HNLP) and polynucleotides which identify and encode HNLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HNLP.Type: ApplicationFiled: October 15, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Henry Yue, Neil C. Corley, Purvi Shah
-
Publication number: 20020099178Abstract: The invention provides a human growth-associated protease inhibitor heavy chain precursor (GAPIP) and polynucleotides which identify and encode GAPIP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of GAPIP.Type: ApplicationFiled: April 5, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Karl J. Guegler, Chandra Patterson
-
Publication number: 20020099195Abstract: The invention provides a human citrate synthase homolog (HUCS) and polynucleotides which identify and encode HUCS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HUCS.Type: ApplicationFiled: November 27, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
-
Publication number: 20020098543Abstract: The invention provides a human prostate associated Ets protein (PRAEP) and polynucleotides which identify and encode PRAEP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PRAEP.Type: ApplicationFiled: May 24, 2001Publication date: July 25, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Karl J. Guegler, Preeti Lal, Neil C. Corley
-
Publication number: 20020091247Abstract: The invention provides novel nucleic acid molecules and encoded proteins associated with response to polycyclic aromatic hydrocarbon exposure. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for screening or purifying ligands and diagnosing, treating or preventing disorders associated with polycyclic aromatic hydrocarbon exposure.Type: ApplicationFiled: April 18, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Matthew R. Kaser, Yalda Azimzai, Henry Yue
-
Publication number: 20020090679Abstract: The present invention provides a human lung growth factor variant (LGFV) and polynucleotides which identify and encode LGFV. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding LGFV and a method for producing LGFV. The invention also provides for agonists, antibodies, or antagonists specifically binding LGFV, and their use, in the prevention and treatment of diseases associated with expression of LGFV. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding LGFV for the treatment of diseases associated with the expression of LGFV. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding LGFV.Type: ApplicationFiled: August 24, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
-
Publication number: 20020091084Abstract: The invention provides a human calcineurin B-like protein (CAB) and polynucleotides which identify and encode CAB. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of CAB.Type: ApplicationFiled: October 25, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Neil C. Corley, Y. Tom Tang
-
Publication number: 20020090712Abstract: The present invention provides three Rab proteins (designated individually as HRABS-1, HRABS-2, and HRABS-3, and collectively as HRABS) and polynucleotides which identify and encode HRABS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRABS and a method for producing HRABS. The invention also provides for use of HRABS and agonists, antibodies, or antagonists specifically binding HRABS, in the prevention and treatment of diseases associated with expression of HRABS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRABS for the treatment of diseases associated with the expression of HRABS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRABS.Type: ApplicationFiled: November 19, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli, Olga Bandman
-
Publication number: 20020091244Abstract: The invention provides a human signal peptide-containing proteins, the polynucleotides which encode them and methods for their use. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.Type: ApplicationFiled: March 5, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Susan K. Sather, Purvi Shah
-
Publication number: 20020090693Abstract: The present invention provides a human sodium-dependent phosphate cotransporter (NAPTR) and polynucleotides which identify and encode NAPTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NAPTR and a method for producing NAPTR. The invention also provides for agonists, antibodies, or antagonists specifically for NAPTR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NAPTR for the treatment of diseases associated with the expression of NAPTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NAPTR. The invention also provides a method for treating disorders associated with decreased phosphate levels by administering NAPTR and a method for treating disorders associated with increased phosphate levels by administering antagonists to NAPTR.Type: ApplicationFiled: November 16, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Olga Bandman
-
Publication number: 20020091249Abstract: The present invention provides a human tumor suppressor (TUPRO-2) and polynucleotides which identify and encode TUPRO-2. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for treating diseases associated with expression of TUPRO-2.Type: ApplicationFiled: October 3, 2001Publication date: July 11, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah